



## Dietary crocin reverses melanoma metastasis

Hamid A Bakshi<sup>1,2,✉,Δ</sup>, Faruck Lukmanul Hakkim<sup>3,4,✉,Δ</sup>, Smitha Sam<sup>2</sup>, Farideh Javid<sup>1</sup>, Luay Rashan<sup>4</sup>

<sup>1</sup> Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD13DH, United Kingdom;

<sup>2</sup> Department of Research, Jawaharlal Nehru Cancer Hospital and Research, Idgah Hills, Bhopal 462001 MP, India;

<sup>3</sup> Mathematics and Science Unit, College of Arts and Applied Sciences, Dhofar University, Salalah 211, Oman;

<sup>4</sup> Frankincense Biodiversity Lab, Research center, Dhofar University, Salalah 211, Oman.

### Abstract

*Crocus sativus* and its bioactive constituent crocin are well known for anti-tumor potential in different models. However, the efficacy of crocin on *in-vivo* melanoma metastasis is not yet reported. In this study, melanoma metastatic model was developed by tail vein injection of B16F-10 cells in to C57BL/6 mice. Metastatic mice treated with two different doses of crocin (250 and 500 µg/kg of bodyweight) for 10 days and parameters such as lung metastasis inhibition, mean survival time, lung hydroxyproline, uronic acid and hexosamine levels were analyzed after 21 days of treatment. Then blood was collected and serum gamma glutamyl transpeptidase (γ-GGT), sialic acid, tumor necrosis factor alpha (TNF-α), interleukin 10 (IL-10), IL-6, IL-2, and TIMP-1 levels were measured. Further, a lung histological examination was done in crocin treated metastatic mice. Subsequently hallmark metastatic parameters such as matrix metalloproteinases (MMPs), extracellular regulated kinase 2 (ERK2), vascular endothelial growth factor (VEGF), and K-ras gene expression were investigated in the lungs of crocin treated metastatic mice. Further, *in-vitro* adhesion, invasion and migration of B16F-10 cells were examined after 24 hours of crocin (5 and 10 µg/mL) treatment. Administration of crocin to tumor bearing C57BL/6 mice reduced the lung metastasis by 85%. Elevated levels of hydroxyproline, uronic acid, hexosamine, serum sialic acid and γ-GGT in metastatic control were found to be significantly reduced in crocin treated mice. Crocin also inhibited expression of MMP-2, MMP-9, ERK-2, K-ras, and VEGF. Crocin reduced the ability of B16F-10 cells invasion ( $P < 0.05$ ), migration ( $P < 0.05$ ) and adhesion by upregulating E-cadherin expression. In conclusion, crocin elicited marked anti-metastatic potential by regulating the metastasis induced biomarkers.

**Keywords:** dietary crocin, melanoma, lung metastasis, B16F-10, E-cadherin, MMPs, ERKs

### Introduction

Malignant melanoma is a potentially fatal form of

skin cancer, with a strong capacity for invasion and metastasis, and high rates of recurrence and mortality<sup>[1-2]</sup>. The median survival following the onset of

<sup>Δ</sup>These authors are equally contributed.

<sup>✉</sup>Corresponding author: Dr. Hamid Bakshi, Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield HD13DH, United Kingdom; Department of Research, Jawaharlal Nehru Cancer Hospital and Research, Idgah Hills, Bhopal 462001 MP, India, Email: [hamid.bakshi@gmail.com](mailto:hamid.bakshi@gmail.com); Dr. Faruck Lukmanul Hakkim, Mathematics and Science Unit, College of Arts and Applied Sciences, Dhofar University, Salalah 211, Oman, Email: [clonehakkim@gmail.com](mailto:clonehakkim@gmail.com).

Received 26 September 2016, Revised 17 February 2017, Accepted 02 June 2017, Epub 10 September 2017

CLC number: R281, Document code: A

The authors reported no conflict of interests.

This is an open access article under the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.

distant melanoma metastasis is just 6-9 months and the five year survival rate is < 5%<sup>[3]</sup>. Melanoma progression and metastasis is necessarily a complex multistep process, as a cancer cell must acquire the ability to survive under anchorage independent conditions, invade through the surrounding stroma and migrate, intravasate into the vascular system; extravasate and subsequently endure a disadvantageous distant environment, adhere to the local tissue, and proliferate<sup>[4]</sup>.

Matrix metalloproteinases (MMPs), which are the most important factor secreted by tumor cells, stromal fibroblasts, or infiltrating inflammatory cells in the tumor microenvironment, have been strongly implicated in multiple stages of invasive and metastatic progression of tumor cells. Furthermore, MMP-9 is important for tumor angiogenesis by enhancing the availability of vascular endothelial cell growth factor (VEGF) in malignant tumors<sup>[5]</sup>. The interaction of VEGF with its cognate receptor VEGFR on the surface of endothelial cells promotes the recruitment and proliferation of endothelial cells *via* the activation of PI3K/Akt and Ras/Raf/MEK/ERK signaling<sup>[6]</sup>. In the majority of cancer patients, by the time of diagnosis of the primary tumor, metastasis to the regional lymph node and/or distant organs has occurred<sup>[7]</sup>. For patients with metastatic melanoma, the current therapy is based on the use of the alkylating agent dacarbazine, and some patients also receive interleukin (IL) - 2 systemically<sup>[8]</sup>. However, 90% of cancer deaths are caused by metastasis that are resistant to conventional therapies such as radiation and chemotherapy<sup>[9]</sup>. There are several drugs that are available for cancer therapy; however, not a single drug emerged as a promising agent to halt these multiple steps of melanoma metastasis.

Plants have a long history of use in the treatment of cancer<sup>[10]</sup>. Almost 60% of drugs approved for cancer treatment are of natural origin<sup>[11]</sup>. Many experimental studies and clinical trials showed that many natural plants played an important role in blocking lung metastasis from primary tumors<sup>[12-14]</sup>. Many herbal drugs such as alcoholic extract of *Thuja occidentalis*<sup>[15]</sup>, aqueous-methanol (3:7) extract of *Boerhaavia diffusa*<sup>[13]</sup>, methanolic extract of *Withania somnifera* roots<sup>[12]</sup>, naturally occurring allyl and phenyl isothiocyanates<sup>[16]</sup>, curcumin<sup>[17]</sup>, and sulphorafane<sup>[14]</sup>, etc. have been reported to inhibit melanoma metastasis.

In this study we tried to explore anti-metastatic potential of *Crocus sativus* L in a melanoma model. *C. sativus* commonly known as saffron which is a dietary herb of the *Iridaceae* family. Principal components of saffron are safranal, crocin, picrocrocin and crocetin and they are pharmacologically active<sup>[18]</sup>. Anti-cancer and anti-tumor properties of saffron have been studied in

several cancer cell lines and animal models<sup>[19]</sup>. It is well reported that saffron can induce apoptosis in different cancer cell lines<sup>[20-21]</sup>. Our previous studies show that saffron can inhibit the growth of different cancer cells such as breast<sup>[22]</sup>, pancreatic<sup>[23]</sup>, and lung<sup>[22]</sup>; and it is also shown to be an active tumor remission agent in Dalton's lymphoma model<sup>[24]</sup>. Extract of Italian *C. sativus* has been shown to be an anti-proliferative agent in B16-F10 melanoma cell line<sup>[25]</sup>. Crocin is a major active component of saffron as reported by our group and elsewhere. Crocin possesses significant anti-proliferation effects on human colorectal cancer cells<sup>[26]</sup>. This carotenoid can induce significant alteration of gene expression profile of T24 (transitional cell carcinoma of bladder) cells. Anti-tumor effects of crocin are mediated at least in part by regulating the cell cycle controlling gene expression<sup>[27]</sup>. However, efficacy of crocin on *in-vivo* melanoma metastasis and its prognostic biomarkers is not yet reported. To address this issue, in this study we delineate the role of crocin on *in-vivo* melanoma lung metastasis.

## Materials and methods

### Plant material and extraction

Saffron stigma was powdered using mortar and pestle. Powdered materials were extracted with ethanol and it is stored in -20°C until use. Active components were identified by HPLC.

### Isolation and characterization of crocin from *C. sativus*

Crocin was isolated from saffron as previously described<sup>[28]</sup>. Briefly, 500 mg saffron was washed thrice with 20 mL ethyl ether, and the residual ether was evaporated in air. It was then suspended in 15 mL of 30% methanol (v/v) in distilled water and stirred for 5 minutes at room temperature. The extract was filtered through a 0.45 µm Millipore filter. It was then diluted with 10 mmol/L phosphate buffered saline (PBS, pH = 7.4), and the concentration of crocin was adjusted to 25 µmol/L, using the coefficient  $\epsilon_{443} = 89,000 \text{ M}^{-1} \text{ cm}^{-1}$  reported for crocin in aqueous solution<sup>[29]</sup>. The crocin structure was elucidated on the basis of <sup>1</sup>HNMR, <sup>13</sup>CNMR, IR, and mass spectral data.

### *In-vitro* anti-metastatic studies

#### Cell lines and culture method

B16F-10 (CRL-6475) melanoma cells were purchased from ATCC, USA. Cells were cultured in Dulbecco's modified eagle's medium (DMEM) with

10% FBS and 1% antibiotics (penicillin/streptomycin) and maintained in humidified cell incubator at 37°C and 5% CO<sub>2</sub>.

#### *Tumor cell adhesion assay*

Tumor cell adhesion assay was carried out as described earlier<sup>[30]</sup>. Briefly, B16F-10 cells were seeded on to type I collagen coated wells of flat-bottomed titer plates, in the absence and presence of crocin (5 µg/mL, 10 µg/mL) and incubated at 37°C for 24 hours. After incubation, cells were washed with PBS and adherent cells were fixed, stained with Giemsa staining and counted under a microscope. Data were presented as mean±SD of triplicates of three independent experiments.

#### *Collagen matrix invasion assay*

Tumor cell invasion assay was carried out in modified Boyden Chamber as described earlier<sup>[31]</sup>. Briefly, the lower compartment of the chamber was filled with serum free DMEM and polycarbonate filter of 8 µm pore size was placed above this. Each filter was coated with 25 µL of type I collagen to form a thin continuous film on the top of the filter. B16F-10 melanoma cells (10<sup>5</sup>/150 µL DMEM) were added to the upper chamber and incubated at 37°C in 5% CO<sub>2</sub> for 24 hours in the presence and absence of different concentrations of crocin (5 µg/mL, 10 µg/mL). After 24 hours of incubation, the cells on the lower surface of the membrane filter were fixed, stained and counted. Data were presented as percentage of invasion of triplicates of three independent experiments.

#### *Tumor cell migration assay*

Tumor cell migration assay was performed similar to invasion assay except that polycarbonate filters were collagen free. Crocin (5 µg/mL, 10 µg/mL) was added along with B16F-10 melanoma cells to the upper compartment of the Boyden chamber. After incubation at 37°C for 24 hours, the number of cells migrating to the lower chamber was determined using a haemocytometer. The results are expressed as percentage motility of triplicates of three independent experiments.

#### *Determination of the effect of dietary crocin on expression of E-cadherin expression*

The whole cell lysate was prepared from crocin (10 µg/mL) treated B16F-10 melanoma cells after 24 hours as described earlier<sup>[32]</sup>. Then whole cell lysate were

resolved in a 10% SDS polyacrylamide gel electrophoretically and electro transferred onto a nitrocellulose membrane. The immunoblots was probed with anti-E-cadherin antibody and visualized with the NBT/BCIP chromogenic substrate and documented.

#### ***In-vivo anti-metastatic studies***

##### *Animals*

Six to eight week old male C57BL/6 mice were used for the study. Mice were maintained under standardized, environmental conditions (22-28°C, 60%-70% relative humidity, 12 hours dark/light cycle and water ad libitum). All the experiments were conducted under the guidelines of Institutional Animal Ethical Committee.

##### *Induction of metastasis*

Metastasis was induced to animals by injecting B16F-10 melanoma cells (1×10<sup>6</sup> cells/animal) *via* the lateral tail vein<sup>[33]</sup>.

##### *Drug preparation*

Crocin was dissolved in minimum volume of ethanol and re-suspended in 1% gum acacia and was given to animals intraperitoneally (i.p) at a concentration of 250 µg and 500 µg/kg body weight.

##### *Determination of in-vivo anti-metastatic potential of crocin*

After induction of metastasis, the mice were divided in to four groups ( $n = 12$ ). Group I animals were kept as normal control and group II as metastatic tumor bearing control receive saline intraperitoneally. Group III and IV received 250 µg and 500 µg/kg body weight, respectively, of crocin intraperitoneally for 10 days consecutively from the day of tumor induction. After the treatment period, six animals from each group were sacrificed and then blood was collected by heart puncture and the serum was separated. Further, lungs were excised and thoroughly washed in PBS and peripheral lung nodules were counted and used to estimate various biochemical parameters such as hydroxyproline, hexosamine, and uronic acid. Serum  $\gamma$ -glutamyl transpeptidase ( $\gamma$ -GT) and sialic acid were estimated by ELISA. The remaining six animals in all of the groups were observed for survival. Histopathological analysis was carried out by fixing both whole lungs, treated and untreated control animals in formaldehyde

(10%) and then dehydrated using gradient alcohol and embedded in paraffin wax. Sections (4 µm) were stained with hematoxylin and eosin.

#### *Determination of the effect of dietary crocin on cytokine and TIMP-1 production in metastatic tumor bearing animals*

Metastasis was induced in 4 groups of C57BL/6 mice ( $n = 12$ ). Group I was normal control and Group II was metastatic control. Group II and III animals had received crocin at 250 µg and 500 µg/kg body weight, respectively, continuously for ten days. Six animals from each group were sacrificed on day 7 and 21 after treatment. Then serum cytokines such as IL-10, IL-6, TNF- $\alpha$ , IL-2 and TIMP-1 were measured using respective ELISA kits by following the manufacturer's instruction.

#### *Gene expression profile of MMP-2, MMP-9, ERK-2, VEGF, and K-ras*

The animals were sacrificed on day 21 after treatment. Then lungs were excised and RNA was extracted using guanidium thiocyanate and cDNA was synthesized as described elsewhere. PCR was performed using specific primers of MMP-2, MMP-9, VEGF, Erk-2, and K-ras. PCR products were resolved by agarose gel electrophoresis and visualized using ethidium bromide dye.

#### *Statistical evaluation*

*In-vitro* data presented as mean $\pm$ SD of triplicates of three independent experiments. *In-vivo* data were presented as mean $\pm$ SD of two triplicates. Experimental data was evaluated by Students' *t*-test and Graph PAD In stat software, Kyplot. Significant differences between each set of data were considered at the confidence level of  $P < 0.05$  and  $P < 0.001$ .

## Results

### **Inhibition of lung metastasis by crocin**

A significant reduction in the number of pulmonary metastatic colonies of B16F-10 melanoma cells were observed in crocin treated mice compared to metastatic tumor bearing control. Administration of crocin 250 and 500 µg/kg of bodyweight reduced percent of lung metastasis by 80% and 85% respectively in a dose dependent manner ( $P < 0.001$ ) (**Fig. 1A**). Further

morphology and histopathological data clearly showed significant reduction of lung metastasis in crocin treated mice compared to untreated metastatic control (**Fig. 1B, C**). These data strongly support the anti-metastatic activity of dietary crocin.

### **Mean survival time and body weight of crocin treated mice**

Mean survival time of crocin (250 and 500 µg/kg of body weight) treated mice was extended up to 27.1 and 31 days respectively compared to untreated metastasis control mice where the survival ended after 26 days of the experimental period (**Fig. 2A**). Furthermore, body weight was measured in normal mice fed with crocin (250 and 500 µg/kg of body weight) for four weeks. We found no significant difference in bodyweight of crocin treated mice compared to control mice (**Fig. 2B**). This data reveals that crocin can be tolerated by mice without eliciting toxicity.

### **Efficacy of crocin on reduction of lung hydroxyproline, uronic acid and hexosamine content**


Elevated levels of hydroxyproline ( $22.17 \pm 0.93$  µg/mg of tissue dry weight), uronic acid ( $360.58 \pm 13.04$  µg/100 mg tissue dry weight), and hexosamine ( $4.36 \pm 0.63$  mg/100 mg tissue dry weight) was observed in metastatic control mice. Moreover, 250 and 500 µg/kg of body weight crocin treatment reduced their levels significantly and brought back near to normal control (**Fig. 3A, B, C**).

### **Role of crocin on serum $\gamma$ -GGT and sialic acid**


As serum sialic acid and  $\gamma$ -GGT are lung metastatic biomarkers in this study, we measured their levels in crocin treated metastatic mice. Both sialic acid ( $21.78 \pm 1.98$  µg/mL) and  $\gamma$ -GGT ( $118.11 \pm 5.83$  nmol p-nitroaniline/mL) levels increased significantly in metastatic mice compared to normal control. Crocin treatment reduced sialic acid and  $\gamma$ -GGT levels significantly at the end of experimental period (**Fig. 4 A, B**).

### ***In-vitro* adhesion, invasion and migration of B16F-10 cells upon crocin treatment**

B16F-10 cells treated with crocin (5 and 10 µg/mL) for 24 hours showed dose-dependent decline in adhesion (85.5% and 73.5%, respectively), invasion (57.2% and 29.2%, respectively), and migration (76.03% and 55.87%, respectively) (**Fig. 5A, B, C**). Further, high expression of E-cadherin was observed in crocin (10 µg/mL) treated B16F-10 cells (**Fig. 5D**).




**Fig. 1** Effect of dietary crocin on lung metastasis. A: Effect of dietary crocin on remission of lung metastasis. B: Effect of dietary crocin on number of lung metastatic nodules. C: Effect of dietary crocin on morphology of lungs of metastasis induced animals. Data are presented as mean $\pm$ SD of two triplicates. \*\* - indicates significant difference at  $P < 0.001$  compare to metastatic control. D: Effect of dietary crocin on histopathological analysis of lungs of metastasis bearing animals. The lungs were dissected out and observed for metastasis (tumor nodules) on day 22 after tumor challenge. For histopathological analysis, the peripheral lung nodule tissue was fixed in 10% buffered formalin and sectioned of 4  $\mu\text{m}$  thickness and embedded in paraffin. Then tissue sections were stained with hematoxylin-eosin and the number and area of metastatic nodules (% tumor area of the whole lung) were measured as described earlier. Scale bar indicates 10  $\mu\text{m}$ .



**Fig. 2 Effect of dietary crocin on mean survival time and body weight.** A: Effect of dietary crocin on mean survival time in tumor bearing animals. Data are presented as mean±SD ( $n = 12$ ). B: Effect of dietary crocin on body weight of mice. Normal mice were fed with different doses of crocin (250 and 500 µg/kg of body weight) and body weight was observed for four weeks on weekly intervals. Data are presented as mean±SD ( $n = 5$ ).

### Activation of TIMP1 and deactivation of MMP (2 and 9), VEGF, ERK2, and K-ras by crocin


As MMP2 and MMP9 facilitates the detachment of tumor cells from primary tumor site and VEGF promotes dissemination *via* ERK2 and Ras, TIMP1 is directly involved in inhibition of MMP's and halt metastatic process. To determine the role of crocin on these signaling molecules in this study, we measured the serum TIMP1 level and expression of MMP's, ERK2 and Ras in crocin treated mice. Serum TIMP-1 level in untreated metastatic tumor bearing control mice was  $553.96 \pm 21.41$  pg/mL and increased with treatment of crocin after 7 days (250 µg/ kg of body weight ( $591.71 \pm 71.33$  pg/mL), 500 µg/ kg of body weight ( $640.20 \pm 24.09$  pg/mL) and 21 days (250 µg/ kg of body weight ( $654.29 \pm 23.67$  pg/mL), 500 µg/ kg of body weight ( $693.8 \pm 35.8$  pg/mL) (**Fig. 6A**). Further expression of MMP-2, MMP-9, VEGF, Erk-2 and Ras (**Fig. 6B**) were considerably reduced by crocin treatment in comparison to metastatic control.




**Fig. 3 Effect of dietary crocin on the lung biochemical parameters.** A: Hydroxyproline content. B: Uronic acid content. C: Hexosamine content. Data are presented as mean±SD of two triplicates. \*and\*\* - indicates significant difference at  $P < 0.05$  and  $P < 0.001$ , respectively, compared to metastatic control.

### Efficacy of dietary crocin on serum TNF- $\alpha$ , IL-6, IL-2, and IL-10

TNF- $\alpha$  (day 7:  $262.12 \pm 8.42$  pg/mL; day 21:  $630.80 \pm 9.54$  pg/mL) and IL-6 (day 7:  $335.08 \pm 3.65$  pg/mL; day 21:  $580.28 \pm 16.6$  pg/mL) were significantly elevated in metastatic mice compared to normal control. Administration of crocin at 250 and 500 µg/kg of body weight reduced TNF- $\alpha$  (day 7:  $153.3 \pm 5.53$  pg/mL and  $145.45 \pm 5.3$  pg/mL, respectively; day 21:  $74.78 \pm 3.42$  pg/mL and  $65.43 \pm 2.33$  pg/mL, respectively), IL-6 (day




**Fig. 4** Effect of dietary crocin on the serum  $\gamma$ -GT and sialic acid levels in metastasis bearing animals. A: Serum  $\gamma$ -GT. B: Serum sialic acid. Data are presented as mean $\pm$ SD of two triplicates. \*and\*\* - indicates significant difference at  $P < 0.05$  and  $P < 0.001$ , respectively, compared to metastatic control.




**Fig. 5** Effect of dietary crocin on adhesion, invasion, migration and E-cadherin expression. B16F-10 melanoma cells were used. A: % of adhesion. B: % of invasion. C: % of migration. D: E-cadherin expression. Data are presented as mean $\pm$ SD of triplicates of three independent experiments. \* and \*\* - indicates significant difference at  $P < 0.05$  and  $P < 0.001$ , respectively, compared to metastatic control.

7:  $72.07 \pm 1.66$  pg/mL and  $68.77 \pm 3.77$  pg/mL, respectively; day 21:  $257.43 \pm 4.39$  pg/mL and  $235.89 \pm 12.2$  pg/mL, respectively) levels significantly ( $P < 0.001$ ) (Fig. 7A, B). In contrast, IL-2 level was reduced on day 7 ( $18.67 \pm 1.3$  pg/mL) and slightly elevated on day 21 ( $630.8 \pm 9.54$  pg/mL) in metastatic mice compared to control. Similarly, IL-10 level also declined on day 7 ( $21.23 \pm 0.95$  pg/mL) and enhanced on day 21 ( $630.8 \pm 9.54$  pg/mL) in metastatic mice

compare to normal control. Treatment with crocin at 250 and 500  $\mu$ g/ kg of body weight enhanced IL-2 (day 7:  $30.2 \pm 0.32$  pg/mL and  $35.46 \pm 2.65$  pg/mL, respectively; day 21:  $48.71 \pm 1.26$  pg/mL and  $51.51 \pm 1.31$  pg/mL respectively), IL-10 (day 7:  $108 \pm 2.51$  pg/mL and  $297 \pm 5.27$  pg/mL, respectively; day 21:  $218 \pm 4.18$  pg/mL and  $312 \pm 2.78$  pg/mL, respectively) levels significantly ( $P < 0.001$ ) (Fig. 7C, D).



**Fig. 6** Effect of dietary crocin on the TIMP-1 level, MMP-2 and MMP-9, VEGF, ERK, and K-Ras expression in metastasis bearing animals. A: TIMP1. \* - indicates significant difference at  $P < 0.05$  compare to metastatic control. B: Expression of MMP-2, MMP-9, VEGF, ERK, and K-Ras. Lane 1: Molecular weight marker; Lane 2: Untreated metastatic tumor bearing control; Lane 3: Treated with Crocin (250 µg/kg body weight); Lane 4: Treated with Crocin (500 µg/kg body weight); Lane 5: GAPDH.



**Fig. 7** Effect of dietary crocin on serum TNF-α, IL-6, IL-2 and IL-10 in in metastatic bearing animals. Data are presented as mean±SD of two triplicates. \* and \*\* - indicates significant difference at  $P < 0.05$  and  $P < 0.001$ , respectively, compared to metastatic control.

**Discussion**

Advanced metastatic melanoma is highly recalcitrant to treatment due to massive spreading and its aggressive nature. Targeted immunotherapy using a cocktail of monoclonal antibodies elicits severe post treatment allergic reactions. In this scenario, recent scientific

efforts have focused on the potential roles of traditional herbs as an alternative and complementary medication for cancer treatment. Extensive research on dietary herbs over the past two decades found that some herbs inhibit different types of tumor growth *in-vivo* and halt *in-vitro* cancer cell proliferation. Many plant derived bioactive constituents, including paclitaxel (from *Taxus*



*brevifolia*), camptothecin (from *Camptotheca acuminata*), podophyllotoxin (from *Podophyllum emodi*), and vinblastine (from *Catharanthus roseus*), have been developed as potential sources of anticancer agents<sup>[34]</sup>. *Crocus sativus* and its active constituent crocin is tumor inhibitory agent in a variety of *in-vivo* tumor models<sup>[19]</sup>. Crocin is the major constituent of *C. sativus* shown to be an effective anti-tumor agent<sup>[22–23]</sup>. However, efficacy of crocin on melanoma metastasis is not yet reported. It is well known that B16F-10 melanoma cells are highly metastatic and form tumor nodules in the parenchyma of the lungs when administered through the tail vein<sup>[33]</sup>. Therefore, in this study, we tested the efficacy of crocin on metastatic melanoma model generated by tail vein injection of B16-F10 cells.

Administration of crocin at 250 and 500 µg/kg of body weight showed significant inhibition of lung metastasis at about 80% and 85% respectively after 21 days of the experimental period (**Fig. 1**). Tumor nodules are metastatic colonies of B16F-10 melanoma cells formed in the lungs, and they initiate lung fibrosis and collagen deposition. Tumor nodule inhibition by drugs correlated with an increase in the life span of the metastatic tumor bearing animals. In our study, mean survival of metastatic mice fed with crocin (500 µg/kg of body weight) extended up to 31 days compare to control (**Fig. 2**). As per the WHO, dietary herbs and their constituents are highly tolerable by the human system compared to synthetic products. Our previous study showed that 300 mg/kg of body weight of *C. sativus* extract administration to normal mice is safe and there was no adverse histopathologic differences observed in the major organs<sup>[35]</sup>. The extent of lung fibrosis during metastasis correlated with lung collagen hydroxyproline content because during lung fibrosis, collagen is deposited massively in the alveolus of the lungs. Fifteen to thirty percent of collagen is hydroxyproline<sup>[36]</sup>, which results in the reduction of pulmonary function. High content of uronic acid results in accumulation of hydroxyproline in lung metastasis. Tumor cells produce uronic acid as a result of oxidation of aldoses of sugar derivatives and leads to the formation of esterified form of glucuronic acid. Conversion of prohydroxyproline to hydroxyproline by prolyl hydroxylase facilitated by the presence of glucuronic acid. In addition glucuronic acid also activates the fiber formation during lung fibrosis<sup>[34]</sup>. Followed by uronic acid, hexosamine is a significant sugar derivative present in the tumor cells. It has an important role in the synthesis of n-acetylneuraminic acid (sialic acid), which is a component of glycolipids present on the surface of tumor cells, thus promoting growth and dissemination<sup>[36]</sup>. In our study, the level of

these molecules was enhanced in the lung tissue of metastatic control. On treatment with crocin, the level of uronic acid, hydroxyproline, and hexosamines brought back significantly and this observation indicates reduced metastatic burden (**Fig. 3A, B, C**). Above mentioned biochemical parameters are interconnected to each other to facilitate lung metastasis and it is directly correlated with the degree of lung metastasis. Overall, our data reveals that levels of hydroxyproline, uronic acid and hexamine in the lungs of metastatic mice treated with crocin (250 and 500 µg/kg of body weight) directly correlated with our lung metastasis remission data (**Fig. 1A**) where we did not observe drastic differences between the doses. However, the molecular mechanism responsible for lack of dose-dependency is unclear.

Rapidly growing tumors need cysteine for intracellular reduced glutathione (GSH) synthesis in order to obtain energy and to sustain growth and subsequent dissemination.  $\gamma$ -glutamyl transpeptidase (GGT) cleaves GSH releasing  $\gamma$ -glutamyl amino acids and cysteinylglycine, which is further cleaved by membrane-bound dipeptidases into cysteine and glycine<sup>[37]</sup>. Further free  $\gamma$ -glutamyl-amino acids, cysteine, and glycine entering the cell serve as GSH precursors<sup>[38]</sup>. Hence, GGT expression facilitates tumor burden and metastatic growth. In our study, we found that serum GGT levels were enhanced in metastatic control but crocin treatment reduced its level significantly (**Fig. 4A**) and it is evidenced from histopathological studies where the metastatic nodules have disappeared after crocin treatment. Sialic acids that are aberrantly expressed on cancer cells appear to facilitate several steps of the metastatic cascade<sup>[39]</sup>. In the current study, we found that elevated serum sialic acid level in metastatic control. High sialic acid expression favors metastasis by facilitating cancer cell detachment and protection from detachment-induced apoptosis (anoikis), enhancing migration and tissue invasion by increasing integrin interactions with the ECM, enabling interactions with endothelial cells to extravasate from the blood stream and form metastases<sup>[40]</sup>. Therefore, inhibiting sialic acid expression could be of crucial importance to halt metastatic cascade and subsequent colonization at distant organs. Our result shows that crocin treatment reduces the level of serum sialic acid significantly at the end of the experimental period (**Fig. 4B**). Molecular mechanism of crocin on reducing sialic acid expression in metastatic mice is unclear; however, it could be due to inhibitory effect of crocin on the metastasis initiation cascade such as adhesion, invasion and migration. The invasion of tumor cells into adjacent tissues, a crucial event in metastasis, involves cell-cell

and cell–ECM interactions<sup>[41]</sup>. These interactions involve a number of adhesive molecules on the cell surface, which have been described in detail<sup>[42]</sup>. Drugs that can inhibit the adhesion of the cells to the ECM may have anti-metastatic potential. To address this issue in this study, we evaluated the potential of crocin on *in-vitro* adhesion, invasion and migration of B16-F10 cells. We found that there was dose-dependent decline in the adhesion of B16-F10 cells with collagen matrix, invasion and migration after crocin treatment (**Fig. 5A, B, C**). Loss of *E*-cadherin facilitates detachment and migration of tumor cells<sup>[43]</sup>. In our study, crocin treatment restores the expression of *E*-cadherin compares to metastatic control (**Fig. 5D**).

Matrix metalloproteinases (MMPs), MMP2 and MMP9 in particular, have been regarded as major molecules that assist tumor cells by cleaving several ECM components and it paves the way for detachment and dissemination during metastasis<sup>[44]</sup>. Tissue inhibitors of metalloproteinases (TIMPs) act as natural inhibitors of MMPs by tightly binding the MMP in a 1:1 stoichiometric ratio and are associated with normal and pathological ECM turnover<sup>[45]</sup>. TIMP inhibits MMP activity, thereby suppressing tumor invasion and metastasis. This phenomenon led us to determine the efficacy of crocin on MMP 2, 9 and TIMP1. Level of TIMP1 reduced in metastatic control but crocin treatment enhanced their levels after 7 and 21 days of the experimental period (**Fig. 6A**). Furthermore, crocin administration inhibited expression of MMP 2 and 9 in lung tissue of treated mice (**Fig. 6B**). Our results are in agreement with previous studies where enhanced TIMP expression can decrease metastasis and inhibit angiogenesis in experimental mouse model<sup>[46]</sup>. Angiogenesis is the hallmark of metastasis and vascular endothelial growth factor (VEGF) is highly expressed in aggressive melanoma cell lines and that melanoma patients with higher VEGF concentrations have a higher rate of relapse<sup>[47]</sup>. VEGF is one of the external stimuli to induce the expression of MMP's and it would facilitate migration. Inhibition of tumor growth has been achieved in different melanoma xenograft models through the use of a number of anti-VEGF strategies<sup>[48]</sup>. As we observed crocin treatment inhibited expression of MMP's, we speculate that crocin could be anti-VEGF component. Our data shows that mice treated with 250 and 500 µg/kg of body weight of crocin completely lost the expression of VEGF compared to metastatic control (**Fig. 6B**). However, the molecular mechanism of crocin on VEGF remains unclear. Survival, proliferation and invasive responses of tumor cells have been shown to be mediated by VEGF through Erk (1/2) pathways<sup>[49]</sup>.

Furthermore, the interaction of VEGF on its cognate receptor VEGFR of endothelial cells requires functional activation of ERK (1/2) pathway, which operates downstream of Ras, is often upregulated in tumors and represents an attractive target for anticancer therapy<sup>[50]</sup>. To identify the role of crocin on Ras/ERK signaling in melanoma lung metastasis in this study, we determine the gene expression pattern of Ras/ERK in crocin treated mice. Crocin (250 and 500 µg/kg of body weight) fed mice was associated with inhibition of Ras and dose dependent decline of ERK2 expression (**Fig. 6B**). Our data suggest that crocin inhibits angiogenesis by suppressing VEGF *via* downregulating ERK2 and its downstream Ras (**Fig. 6B**). Similarly, thujone, a monoterpene that inhibits melanoma lung metastasis by downregulating ERK (1/2) and its downstream Ras<sup>[50]</sup>.

Cytokines play a pivotal role in triggering metastasis. TNF- $\alpha$  shown to be an important cytokine mediator of cancer metastasis in murine models<sup>[51]</sup>. Ocvirk *et al.* found that concentrations of TNF- $\alpha$  were significantly higher in metastatic melanoma patients<sup>[52]</sup> and Cubillos *et al.* suggested that the reduction in the number of metastasis may be related to the effect of blocking TNF activity in melanoma cells<sup>[53]</sup>. Similarly, in our study, we found that the serum TNF- $\alpha$  level increased significantly in metastatic control mice but crocin treatment reduced its level after 7 and 21 days of the experimental period (**Fig. 7A**). Furthermore, in this study, we measured serum interleukin (IL) 2, 6, and 10 levels in metastatic and crocin treated mice. IL-6 is secreted by malignant melanoma cells, and the serum level is associated with advanced stages of the disease. Noticeably, serum IL-6 level was found to be significantly high in advanced melanoma patients<sup>[54]</sup>. In our study, we found that crocin treatment significantly reduced serum IL-6 level compared to metastatic control (**Fig. 7B**). This implies that immune modulating ability of crocin in melanoma metastasis. IL-2 has been used for more than two decades in the therapy of metastatic melanoma which, in some of treated patients, resulted in induction of long-lasting remission<sup>[55]</sup>. Forced expression of IL-10 in human melanoma cells did not enhance tumor growth and metastatic potential in nude mice, but rather significantly inhibited their tumorigenicity and metastatic capabilities<sup>[56]</sup>. In the current study, both IL-2 and IL-10 levels were enhanced significantly by crocin treatment at the end of the experimental period (**Fig. 7C, D**). IL-10 has been shown to inhibit the production of IL-1, IL-6, IL-8, TNF- $\alpha$ <sup>[57]</sup> and forced expression of IL-10 suppressed VEGF and MMP-9, secreted by tumor-associated macrophages in

melanoma model<sup>[56]</sup>. Our results are in agreement with this report since crocin treatment elevated the levels of IL-10 and IL-2.

In conclusion, our experimental data has clearly demonstrated that dietary crocin strongly inhibits lung metastasis of B16F-10 melanoma cells *in-vivo*. Furthermore, crocin suppresses *in-vitro* adhesion, invasion, and migration by upregulating E-cadherin. However, extensive preclinical study is required to transform dietary crocin as a cancer therapeutic agent for melanoma patients.

## References

- [1] Shore RN, Shore P, Monahan NM, et al. Serial screening for melanoma: measures and strategies that have consistently achieved early detection and cure[J]. *J Drugs Dermatol*, 2011, 10(3): 244–252.
- [2] Boyle GM. Therapy for metastatic melanoma: an overview and update[J]. *Expert Rev Anticancer Ther*, 2011, 11(5): 725–737.
- [3] Houghton AN, Polsky D. Focus on melanoma[J]. *Cancer Cell*, 2002, 2(4): 275–278.
- [4] Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis[J]. *Science*, 2011, 331(6024): 1559–1564.
- [5] Zheng H, Takahashi H, Murai Y, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma[J]. *Anticancer Res*, 2006, 26(5A): 3579–3583.
- [6] Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis[J]. *World J Gastroenterol*, 2003, 9(6): 1144–1155.
- [7] Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency[J]. *Free Radic Biol Med*, 2003, 34(8): 969–986.
- [8] de Melo FM, Braga CJ, Pereira FV, et al. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10[J]. *Immunol Cell Biol*, 2015, 93(1): 86–98.
- [9] Gupta GP, Massagué J. Cancer metastasis: building a framework[J]. *Cell*, 2006, 127(4): 679–695.
- [10] Hartwell JL. *Plants Used Against Cancer: A Survey*[M]. Lawrence, MA: Quarterman Publications, 1982; 438–439.
- [11] Sithranga Boopathy N, Kathiresan K. Anticancer drugs from marine flora: an overview[J]. *J Oncol*, 2010, 2010: 214186.
- [12] Leyon PV, Kuttan G. Effect of *Withania somnifera* on B16F-10 melanoma induced metastasis in mice[J]. *Phytother Res*, 2004, 18(2): 118–122.
- [13] Leyon PV, Lini CC, Kuttan G. Inhibitory effect of *Boerhaavia diffusa* on experimental metastasis by B16F10 melanoma in C57BL/6 mice[J]. *Life Sci*, 2005, 76(12): 1339–1349.
- [14] Thejass P, Kuttan G. Antimetastatic activity of Sulforaphane[J]. *Life Sci*, 2006, 78(26): 3043–3050.
- [15] Sunila ES, Kuttan G. A preliminary study on antimetastatic activity of *Thuja occidentalis* L. in mice model[J]. *Immunopharmacol Immunotoxicol*, 2006, 28(2): 269–280.
- [16] Manesh C, Kuttan G. Effect of naturally occurring allyl and phenyl isothiocyanates in the inhibition of experimental pulmonary metastasis induced by B16F-10 melanoma cells[J]. *Fitoterapia*, 2003, 74(4): 355–363.
- [17] Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin[J]. *Cancer Lett*, 1999, 141(1-2): 159–165.
- [18] Rios JL, Recio MC, Giner RM, et al. An update review of saffron and its active constituents[J]. *Phytother Res*, 1996, 10: 189–193.
- [19] Abdullaev FI, Espinosa-Aguirre JJ. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials[J]. *Cancer Detect Prev*, 2004, 28(6): 426–432.
- [20] Mousavi SH, Tavakkol-Afshari J, Brook A, et al. Direct toxicity of Rose Bengal in MCF-7 cell line: role of apoptosis[J]. *Food Chem Toxicol*, 2009, 47(4): 855–859.
- [21] Mousavi SH, Tavakkol-Afshari J, Brook A, et al. Role of caspases and Bax protein in saffron-induced apoptosis in MCF-7 cells[J]. *Food Chem Toxicol*, 2009, 47(8): 1909–1913.
- [22] Bakshi H, Touseef T, Fassal G, et al. *Crocus sativus* L. prevents progression of cell growth and enhances cell toxicity in human breast cancer and lung cancer cell lines[J]. *Int J Pharma. Life Sci*, 2012, 2(1): 120–124.
- [23] Bakshi H, Sam S, Rozati R, et al. DNA fragmentation and cell cycle arrest: a hallmark of apoptosis induced by crocin from Kashmiri saffron in a human pancreatic cancer cell line[J]. *Asian Pac J Cancer Prev*, 2010, 11(3): 675–679.
- [24] Bakshi HA, Sam S, Feroz A, et al. Crocin from Kashmiri saffron (*Crocus sativus*) induces in-vitro and in-vivo xenograft growth inhibition of Dalton's lymphoma (DLA) in mice[J]. *Asian Pac J Cancer Prev*, 2009, 10(5): 887–890.
- [25] Gismondi A, Serio M, Canuti L, et al. Biochemical, Antioxidant and Antineoplastic Properties of Italian Saffron (*Crocus sativus* L.)[J]. *Am J Plant Sci*, 2012, 3: 1573–1580.
- [26] Aung HH, Wang CZ, Ni M, et al. Crocin from *Crocus sativus* possesses significant anti-proliferation effects on human colorectal cancer cells[J]. *Exp Oncol*, 2007, 29(3): 175–180.
- [27] Lv CF, Luo CL, Ji HY, et al. [Influence of crocin on gene expression profile of human bladder cancer cell lines T24][J]. *Zhongguo Zhong Yao Za Zhi*, 2008, 33(13): 1612–1617.
- [28] Lussignoli S, Fraccaroli M, Andrioli G, et al. A microplate-based colorimetric assay of the total peroxy radical trapping capability of human plasma[J]. *Anal Biochem*, 1999, 269(1): 38–44.
- [29] Jørgensen LV, Andersen HJ, Skibsted LH. Kinetics of reduction of hypervalent iron in myoglobin by crocin in aqueous solution [J]. *Free Radic Res*, 1997, 27(1): 73–87.
- [30] Kang IC, Kim DS, Jang Y, et al. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis [J]. *Biochem Biophys Res Comm*, 2000, 275(1): 169–173.

- [31] Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in-vitro assay for quantitating the invasive potential of tumor cells[J]. *Cancer Res*, 1987, 47(12): 3239–3245.
- [32] Shin DH, Kim OH, Jun HS, et al. Inhibitory effect of capsaicin on B16-F10 melanoma cell migration via the phosphatidylinositol 3-kinase/Akt/Rac1 signal pathway[J]. *Exp Mol Med*, 2008, 40(5): 486–494.
- [33] Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis[J]. *Cancer Res*, 1978, 38(9): 2651–2660.
- [34] Hsu HF, Huang KH, Lu KJ, et al. Typhonium blumei extract inhibits proliferation of human lung adenocarcinoma A549 cells via induction of cell cycle arrest and apoptosis[J]. *J Ethnopharmacol*, 2011, 135(2): 492–500.
- [35] Bakshi HA, Hakkim FL, Sam S. Molecular Mechanism of Crocin Induced Caspase Mediated MCF-7 Cell Death: In-Vivo Toxicity Profiling and Ex Vivo Macrophage Activation[J]. *Asian Pac J Cancer Prev*, 2016, 17(3): 1499–1506.
- [36] Voet D, Voet JG. *Biochemistry*[M]. New York: Wiley, 1995, 157–258.
- [37] Meister A. Selective modification of glutathione metabolism[J]. *Science*, 1983, 220(4596): 472–477.
- [38] Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy [J]. *Pharmacol Ther*, 1991, 51(2): 155–194.
- [39] Büll C, Stoel MA, den Brok MH, et al. Sialic acids sweeten a tumor's life[J]. *Cancer Res*, 2014, 74(12): 3199–3204.
- [40] Bull C, den Brok MH, Adema GJ. Sweet escape: Sialic acids in tumor immune evasion[J]. *Biochim Biophys Acta*, 2014, 1846(1): 238–246.
- [41] Zhao Y, Sato Y, Isaji T, et al. Branched N-glycans regulate the biological functions of integrins and cadherins[J]. *FEBS J*, 2008, 275(9): 1939–1948.
- [42] Kurschat P, Mauch C. Mechanisms of metastasis[J]. *Clin Exp Dermatol*, 2000, 25(6): 482–489.
- [43] Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression[J]? *Oncogene*, 2008, 27(55): 6920–6929.
- [44] Brezillon S, Zeltz C, Schneider L, et al. Lumican inhibits B16F1 melanoma cell lung metastasis[J]. *J Physiol Pharmacol*, 2009, 60(4 Suppl 4): 15–22.
- [45] Offenbergh H, Brünner N, Mansilla F, et al. TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles[J]. *Mol Oncol*, 2008, 2(3): 233–240.
- [46] Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer[J]. *Oncogene*, 2002, 21(14): 2245–2252.
- [47] Osella-Abate S, Quagliano P, Savoia P, et al. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course[J]. *Melanoma Res*, 2002, 12(4): 325–334.
- [48] Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration[J]. *Cancer Res*, 2002, 62(16): 4645–4655.
- [49] So J, Wang FQ, Navari J, et al. LPA-induced epithelial ovarian cancer (EOC) in-vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2)[J]. *Gynecol Oncol*, 2005, 97(3): 870–878.
- [50] Siveen KS, Kuttan G. Thujone inhibits lung metastasis induced by B16F-10 melanoma cells in C57BL/6 mice[J]. *Can J Physiol Pharmacol*, 2011, 89(10): 691–703.
- [51] Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation[J]. *J Exp Med*, 1988, 167(3): 1211–1227.
- [52] Ocvirk J, Stabuc B, Rudolf Z, et al. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients[J]. *Melanoma Res*, 2000, 10(3): 253–258.
- [53] Cubillos S, Scallon B, Feldmann M, et al. Effect of blocking TNF on IL-6 levels and metastasis in a B16-BL6 melanoma/mouse model[J]. *Anticancer Res*, 1997, 17(3C): 2207–2211.
- [54] Moretti S, Chiarugi A, Semplici F, et al. Serum imbalance of cytokines in melanoma patients[J]. *Melanoma Res*, 2001, 11(4): 395–399.
- [55] Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer [J]. *Cancer J*, 2010, 16(4): 392–398.
- [56] Huang S, Ullrich SE, Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience[J]. *J Interferon Cytokine Res*, 1999, 19(7): 697–703.
- [57] Howard M, O'Garra A. Biological properties of interleukin 10 [J]. *Immunol Today*, 1992, 13(6): 198–200.